Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
NCT ID: NCT04354545
Last Updated: 2022-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
75 participants
OBSERVATIONAL
2021-04-01
2024-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
NCT07076303
An App-based Instructional Platform to Improve Eye Drop Recall
NCT06045390
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
NCT04577300
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
NCT01408472
Survey of Patients Taking IOP-Lowering Eye Drops
NCT02384772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
Xiidra (Lifitegrast ophthalmic solution) 5%
FDA approved lifitegrast opthalmic solution eye drop
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xiidra (Lifitegrast ophthalmic solution) 5%
FDA approved lifitegrast opthalmic solution eye drop
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-described symptoms of ocular surface discomfort
* Xiidra is being prescribed as part of the subject's standard care
Exclusion Criteria
* current use of topical cyclosporine
* current use of topical steroids
* incisional ocular surgery within 6 months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Benjamin B. Bert, MD
Health Sciences Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Doheny Eye Center UCLA
Fountain Valley, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-000843
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.